Form D · Pharmaceuticals
Vesalius Longevity Labs Inc.
Vancouver, A1 · CIK 0002131865
Offering snapshot reported Nov 3, 2026 · SEC filing
- Reported sold
- $30.1M Offering amount: $30.1M
- Investors reported
- 62 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 28, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 3, 2026 | Initial | $30,112,500 | No comparison | 62 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-603399
Total Offering Amount represents the price of 60,225,000 common shares at a deemed price of $0.50 per share.
Source: Form D, filed Nov 3, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Adelman | Director |
| Pradeep Albert | Executive |
| Lee Applbaum | Director |
| Christopher R Cooper | Executive |
| Joel Leonoff | Director |
| Kevin Mayer | Director |
| Robert Mccue | Director |
| James Mcroberts | Director |
| Kevin Serre | Director |
| Timmi Stump | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Suite 1500 1055 West Georgia Street
Vancouver, A1, V6E 4N7
Vancouver, A1, V6E 4N7